Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HealthLinx signs up South Korean distributor for ovarian cancer Dx

This article was originally published in Clinica

Executive Summary

Australian company HealthLinx has made Seoul Clinical Laboratories (SCL) the exclusive distributor of its OvPlex ovarian cancer diagnostic test in South Korea. SCL, said to be South Korea’s largest clinical pathology reference laboratory, will distribute the product once it has gained approval from the South Korea Food and Drug Administration. OvPlex is currently being assessed in a 220-patient study that began earlier this year. Under the terms of the distribution deal, SCL will co-fund the study. Other financial details of the agreement were not disclosed. In South Korea, around 250,000 ovarian cancer tests are performed each year. According to Melbourne-based HealthLinx, the disease is experiencing a 15% annual growth rate in the country. In February, HealthLinx launched OvPlex in the UK through distribution partner Intus Healthcare and has introduced the product in Singapore. At the time of the deal, HealthLinx said that it had opened distribution discussions in other European countries, as well as China.

You may also be interested in...



Alere aided by professional diagnostics sales in fourth quarter

Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.

Integra and Stout to work on expandable interbody device

Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.

Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials

Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel